Novel Glutathione leads to longer remission in ovarian cancer

Previously treated ovarian cancer patients, who have failed after first line drugs such as taxol and platins, represebnt a difficult type of patient to successfully treat. Conventional agents such as topotecan and liposomal doxorubicin are attended with median survival rates of 35-40 weeks in this second line chemotherapy situation. In a recently reported trial from the USA, a new drug TLK286 (Telik Inc. San Francisco) a glutsathione (activated in cancer cells by glutathionbe S transferase) achieved a 56 week median survival in this situation - a result that is crying out for repeating by others and a spark for further research in hihs field.